Make your money go further for just 25p per day

PREMIUM

Mega-Trends: A troubling 2021 opens opportunities for recovery

11/02/2022

Mega trends

Mega-Trends Investor's Champion logo
  • The Mega-Trends portfolio ended 2021 down 4%
  • The portfolio remains on the hunt for exciting innovation which is not yet being recognised by the market 

Without a repeat of star stock Tesla’s (US: TSLA) 2020 portfolio contribution (a 12.5-fold return), the Investor’s Champion Mega-Trends Portfolio struggled to maintain its pace of growth in 2021. After a decent, market-beating start to the year, momentum faltered in March as the tide turned on the high-growth, high-risk sections of the stock market. The portfolio closed the year down 7.3%.

But it’s not all bad news. The original £40,000 investment we made in 20 stocks…

Continue reading our content…

Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
  • Unlimited access to our market-beating portfolios
  • In-depth coverage of many of the world’s great companies
  • Unique insights from our top research team
Register FREE for access to limited content.
  • Company and markets insights
  • Sponsored content
  • Podcasts

Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Alphabet

Episode 30 of the Investor’s Champion Podcast

11/08/2024 · Podcasts

In this episode of the Investors Champion Podcast, hosts Chris and Lee kick off with a…


Game delights | Consumer facing weakness | Tech delivers

02/08/2024 · Portfolio

Most of our Ultimate Stocks continue to deliver excellent results although it’s more of a struggle…


More on CRISPR Therapeutics

Mega-Trends: next big thing is a step closer

27/11/2023 · Portfolio

A technology which could have an even bigger impact upon the world than AI has just…


An immense opportunity

30/08/2022 · Portfolio

CRISPR Therapeutics’ therapy for sickle cell disease could be available next year; this is incredibly exciting…


More on IDEXX Laboratories

Ultimate Stocks: July ‘22 portfolio update

19/07/2022 · Portfolio

Our Ultimate Stocks portfolio delivers relative outperformance over a very difficult period for stock markets. Our…


Mega-Trends: A troubling 2021 opens opportunities for recovery

11/02/2022 · Portfolio

Sign-up to our free email updates

SIGN UP